Newsroom
Sorted by: Latest
-
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law...
-
SCHL Investors with $100,000 in Losses Have Opportunity to Join Scholastic Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--SCHL Investors with $100,000 in Losses Have Opportunity to Join Scholastic Corporation Fraud Investigation with SBS Law...
-
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases...
-
Sky9 Capital Expands Into Europe With the Opening of a New Office in Paris
PARIS--(BUSINESS WIRE)--Sky9 Capital, a global Asia-rooted technology venture capital firm with approximately $2 billion in assets under management, announced the opening of its Paris office at Station F, Europe's largest startup campus. Founded by veteran venture capitalist Ron Cao, Sky9 has invested in and supported over 150 Asia- and US-based startups, resulting in 16 global IPOs and 19 M&A exits over more than a decade of investing. Sky9 Capital is headquartered in Singapore and has off...
-
Publix Charities Donates $500,000 to Support Hurricane Isaias Relief Efforts
LAKELAND, Fla.--(BUSINESS WIRE)--Publix Super Markets Charities is making a $500,000 donation to United Way to help fund relief efforts for areas impacted by Hurricane Isaias. “Hurricane Isaias brought disruption and uncertainty to many of the communities we serve,” said Publix Charities Executive Director John Doran. “Supporting them during times of need is an important part of who we are, and we’re grateful for the opportunity to assist through an organization that helps those affected locall...
-
KAON Broadband Showcases Field-Proven prpl Deployments and Wi-Fi 8-Ready Platforms at prpl Summit 2026
VIENNA--(BUSINESS WIRE)--The prpl Foundation highlighted KAON Broadband’s participation in the prpl Summit 2026 as an Innovation Partner for Technical Day and a Technology Partner for Business Day. This partnership underscores KAON Broadband’s continued commitment to advancing open-source broadband platforms, backed by its extensive experience in commercial operator deployments and ongoing development of next-generation connectivity solutions. KAON Broadband has played an active role in bringin...
-
The Chemours Company Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CC
LOS ANGELES--(BUSINESS WIRE)--The Chemours Company Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CC...
-
Netcapital Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NCPL
LOS ANGELES--(BUSINESS WIRE)--Netcapital Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NCPL...
-
GoodVision AI to Showcase AI Inference Infrastructure at TechCrunch Disrupt 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--GoodVision AI (“GoodVision”), a developer of next-generation AI compute infrastructure purpose-built for inference, today announced that it will exhibit at TechCrunch Disrupt 2026, taking place October 13–15, 2026, at Moscone West in San Francisco. The appearance follows the September 11 approval of GoodVision’s business combination with Calisa Acquisition Corp. (Nasdaq: ALIS), marking a new stage in the company’s development as it expands its AI inference...
-
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...